Atlanta, GA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded an existing contract with a 6 facility, Oracle Cerner-EHR based health system. The system has been using eValuator for pre-bill code auditing for more than 3 years and has elected to add RevID’s automated charge reconciliation for improved pre-bill revenue integrity. The client also added the eValuator Pro Fee module and extended the term of the overall agreement for an additional 3 years.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation and eValuator’s automated pre-bill code auditing ensure that providers can accurately capture, bill and ultimately be paid for all the care they provide.
“We are thrilled our client is expanding their ability to ensure accurate compensation for all of the care they’ve provided through our industry leading solutions” stated Ben Stilwill, President and Chief Executive Officer, Streamline. “We are confident that bringing together RevID’s charge reconciliation and eValuator’s pre-bill code audting technology in one health system will have a synergistic impact, resulting in significant improvements to this system’s revenue cycle. We look forward to sharing the results of this first enterprise client with our existing clients and prospects.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
Contact
Jacob Goldberger
Vice President of Finance
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.29 |
| Daily Change: | -0.0019 -0.65 |
| Daily Volume: | 244,181 |
| Market Cap: | US$17.080M |
April 29, 2024 February 07, 2024 December 13, 2023 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
